Ventyx Biosciences’ (VTYX) “Market Perform” Rating Reiterated at Lifesci Capital

Lifesci Capital reiterated their market perform rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a report released on Thursday morning,Benzinga reports. Lifesci Capital currently has a $14.00 price target on the stock.

VTYX has been the subject of several other reports. Canaccord Genuity Group downgraded shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $16.00 to $14.00 in a research report on Thursday. UBS Group reissued a “neutral” rating and set a $14.00 price target (down from $20.00) on shares of Ventyx Biosciences in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Wednesday, November 5th. Finally, Oppenheimer raised their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Eight analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $14.86.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $13.81 on Thursday. The stock has a 50-day simple moving average of $9.27 and a 200 day simple moving average of $5.30. The stock has a market capitalization of $985.48 million, a P/E ratio of -9.21 and a beta of 1.23. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $25.00.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.13. Research analysts forecast that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new stake in Ventyx Biosciences during the second quarter valued at $71,000. Affinity Asset Advisors LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter worth approximately $9,707,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Ventyx Biosciences by 8.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock worth $2,023,000 after buying an additional 73,601 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at $148,000. Finally, Pallas Capital Advisors LLC acquired a new stake in Ventyx Biosciences in the second quarter worth $38,000. Institutional investors own 97.88% of the company’s stock.

Trending Headlines about Ventyx Biosciences

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.